Forecast Period | 2025-2029 |
Market Size (2023) | USD 1.20 Billion |
Market Size (2029) | USD 1.57 Billion |
CAGR (2024-2029) | 4.53% |
Fastest Growing Segment | Immuno Diagnostics |
Largest Market | North Mexico |
Market Overview
Mexico
In-Vitro Diagnostics (IVD) Market was valued at USD 1.20 billion in 2023 and is
anticipated to project steady growth in the forecast period with a CAGR of 4.53%
through 2029. The Mexico In-Vitro Diagnostics (IVD) market is a dynamic and
rapidly evolving sector within the healthcare industry. It includes a broad
array of diagnostic tests and technologies designed to analyze biological
samples outside the human body. Key advancements in this field, such as
molecular diagnostics, point-of-care testing, and automation, are significantly
expanding the capabilities and applications of IVD products.
To
succeed in the Mexican IVD market, companies must prioritize innovation,
diversify their product offerings, and align with emerging healthcare trends.
The market is positioned for robust growth, driven by increasing demand for
diagnostic testing, ongoing technological advancements, a heightened emphasis
on preventive healthcare, and supportive economic and policy factors.
To
capture these growth opportunities and maintain a competitive edge, companies
need to stay attuned to regional and technological developments, navigate
regulatory complexities, and employ strategic approaches. Adapting to these
trends and leveraging competitive strategies will be crucial for enhancing
market presence and driving future success.
Key Market Drivers
Increasing Prevalence of
Chronic Diseases
The
increasing prevalence of chronic diseases is a significant driver of growth in
the Mexico In-Vitro Diagnostics (IVD) market. Chronic diseases, such as
diabetes, cardiovascular conditions, and cancer, require ongoing management and
monitoring, which significantly influences the demand for diagnostic products
and services.
Chronic
diseases necessitate regular diagnostic testing to monitor disease progression,
manage treatment, and prevent complications. As the prevalence of these
diseases rises, so does the need for various diagnostic tests. Patients with
chronic conditions often require frequent testing to manage their health
effectively. For example, diabetics need regular glucose monitoring, while
individuals with cardiovascular diseases require lipid panels and other
cardiovascular markers. Regular diagnostic tests are essential for assessing
the effectiveness of treatment plans and making necessary adjustments. This
ongoing need drives the demand for a wide range of diagnostic tests and
technologies. Increased focus on early detection and preventive care for
chronic diseases leads to higher demand for diagnostic screenings, contributing
to market growth. Companies should focus on developing and offering diagnostic
products that cater to the specific needs of chronic disease management.
Innovations in monitoring technologies and tests that provide comprehensive
health data will be crucial for meeting this demand.
The
rise of personalized medicine is closely linked to the management of chronic
diseases. Personalized medicine involves tailoring treatment and management
plans based on individual patient profiles, which relies heavily on accurate
and detailed diagnostic information. Personalized medicine requires detailed
diagnostic information to create customized treatment plans for chronic disease
patients. This drives the demand for advanced diagnostic tests that can provide
precise and individualized data. Advances in biomarker research for chronic
diseases lead to the development of new diagnostic tests and technologies.
These biomarkers are used to predict disease risk, monitor progression, and
evaluate treatment responses. The integration of diagnostic data with digital
health platforms for personalized care enhances the management of chronic
diseases and drives demand for advanced diagnostic solutions. Companies should
invest in research and development to create diagnostic tests that support
personalized medicine initiatives. Collaborations with research institutions
and healthcare providers to develop and validate new biomarkers and diagnostic
technologies will be key to capturing this market segment.
The
increasing prevalence of chronic diseases is prompting the expansion of
healthcare services and infrastructure to accommodate the growing need for
diagnostic testing and management. The establishment of new healthcare
facilities, diagnostic centers, and specialized clinics is driven by the need
to provide comprehensive care for chronic disease patients. This expansion
creates opportunities for the distribution and use of IVD products. Upgraded
healthcare facilities often integrate advanced diagnostic technologies to
enhance patient care and disease management. This integration drives the
adoption of new IVD products and services. The expansion of healthcare services
includes training healthcare professionals in the use of advanced diagnostic
technologies, which supports the growth of the IVD market. Companies should
align their strategies with the expansion of healthcare infrastructure by
partnering with healthcare providers and institutions. Providing training and
support for the effective use of diagnostic technologies can further enhance
market penetration.
The
economic burden of chronic diseases and related policy initiatives also
contribute to the growth of the IVD market. Governments and health
organizations are increasingly focused on addressing the economic impact of
chronic diseases through improved diagnostic and treatment strategies. Government
policies and funding programs aimed at chronic disease management often include
provisions for diagnostic testing and healthcare services. This drives demand
for IVD products and services. Economic incentives and subsidies for diagnostic
tests can make advanced technologies more accessible to patients and healthcare
providers, supporting market growth. Public health campaigns focusing on
chronic disease prevention and management increase awareness and drive the
adoption of diagnostic tests. Engaging with government and health organizations
to align with policy initiatives and funding programs can open new market
opportunities. Companies should also consider developing cost-effective
diagnostic solutions to address economic constraints and enhance accessibility.
Technological Advancements and
Innovation
Technological
advancements and innovation are pivotal drivers of growth in the Mexico
In-Vitro Diagnostics (IVD) market. These advancements enhance the accuracy,
efficiency, and scope of diagnostic testing, creating significant opportunities
for market expansion.
Technological
advancements have led to the development of highly accurate and efficient
diagnostic tests. Improved accuracy and faster results are critical for
effective disease detection and management. Innovations such as next-generation
sequencing (NGS), polymerase chain reaction (PCR) technology, and
high-throughput screening platforms offer enhanced sensitivity and specificity.
These technologies enable more precise detection of diseases at an earlier
stage. Automation and advancements in diagnostic instrumentation have
significantly reduced the time required to obtain test results. Faster
turnaround times improve patient outcomes by facilitating timely treatment
decisions. The integration of artificial intelligence (AI) and machine learning
in diagnostic tools enhances data analysis, pattern recognition, and predictive
capabilities. This results in more accurate diagnoses and personalized
treatment plans. Companies should prioritize investments in cutting-edge
technologies and automation to stay competitive. Offering diagnostic solutions
with advanced accuracy and efficiency will meet the growing demand for
high-quality testing and improve market positioning.
Technological
innovations expand the range of diagnostic applications, addressing a broader
spectrum of medical conditions and disease states. This expansion drives market
growth by increasing the relevance and utility of IVD products. Advances in
genomics and proteomics enable the development of comprehensive test panels
that cover multiple biomarkers and conditions. This expansion supports more
holistic and detailed diagnostic assessments. Technological progress allows for
the identification of new disease markers and targets, leading to the creation
of novel diagnostic tests for previously underserved conditions. This
innovation opens up new market segments and opportunities. Innovations in
portable and point-of-care diagnostic devices make it possible to conduct tests
outside traditional laboratory settings. This broadens the scope of diagnostic
applications and enhances accessibility. Companies should invest in research
and development to explore new diagnostic applications and expand their product
portfolios. Collaborating with research institutions to discover and validate
new disease markers and test methods can drive market growth and innovation.
The
integration of diagnostic technologies with digital health platforms and remote
monitoring solutions is transforming the IVD market. This integration enhances
patient management and expands the reach of diagnostic services. Integration
with digital health platforms enables remote diagnostics and telemedicine
services, allowing patients to access testing and consultations from home. This
trend supports the growth of remote and decentralized diagnostic solutions. Technological
advancements in data management and analytics facilitate the collection,
storage, and interpretation of diagnostic data. Enhanced data capabilities
improve patient monitoring, trend analysis, and clinical decision-making. Digital
health tools and mobile applications empower patients to actively engage in
their health management, track test results, and receive real-time feedback.
This increases the adoption of diagnostic testing and promotes proactive
healthcare. Companies should focus on developing diagnostic solutions that
integrate seamlessly with digital health platforms and remote monitoring
systems. Investing in digital health technologies and forming strategic
partnerships with tech firms can enhance market reach and patient engagement.
Technological
advancements also contribute to improved regulatory and quality compliance,
ensuring that diagnostic products meet stringent standards and regulations. Innovations
in automation and robotics enhance quality control processes, reducing human
error and ensuring consistent product performance. This supports compliance
with regulatory requirements and industry standards. Advances in validation
techniques and technologies streamline the process of proving the accuracy and
reliability of diagnostic tests. This facilitates faster regulatory approvals
and market entry. Technological innovations often align with global regulatory
standards, allowing companies to meet international requirements and expand
their market presence beyond Mexico.
Growing Focus on Preventive
Healthcare and Early Diagnosis
The
growing focus on preventive healthcare and early diagnosis is a significant
driver of the Mexico In-Vitro Diagnostics (IVD) market. This shift towards
proactive health management emphasizes early detection and prevention of
diseases, which has a profound impact on the demand for diagnostic products and
services.
Preventive
healthcare emphasizes the importance of regular screening to detect diseases
before symptoms arise. This approach leads to a higher demand for diagnostic
tests that facilitate early disease detection and intervention. Public health
campaigns and government programs increasingly focus on routine screening for
various conditions, such as cancer (e.g., mammograms, Pap smears),
cardiovascular diseases, and diabetes. These initiatives drive demand for IVD
products that are used in these screenings. Early diagnosis of chronic
conditions allows for better management and prevention of disease progression.
This drives the need for diagnostic tests that monitor risk factors and disease
markers regularly. As the focus on screening grows, there is an increased need
for a broad range of diagnostic tests, including those for early-stage diseases
and asymptomatic conditions. Companies should invest in developing and
marketing diagnostic tests that cater to preventive screening programs.
Aligning with public health initiatives and creating comprehensive screening
solutions can enhance market opportunities and growth.
Technological
advancements have made it possible to perform more accurate and efficient
diagnostic tests, which supports the focus on preventive healthcare and early
diagnosis. Innovations in diagnostic technologies, such as next-generation
sequencing (NGS) and advanced imaging techniques, provide more precise and
reliable results. This enables earlier detection of diseases with higher
accuracy. Developments in non-invasive diagnostic tests, such as liquid
biopsies and wearable health monitors, facilitate early diagnosis without the
need for invasive procedures. This aligns with preventive healthcare goals and
increases patient compliance. Advances in point-of-care testing (POCT)
technologies allow for rapid diagnostic results at the site of care, improving
accessibility and encouraging early diagnosis. Investing in and adopting
cutting-edge diagnostic technologies will be essential for meeting the demand
for early and accurate disease detection. Companies should focus on developing
innovative solutions that support preventive healthcare objectives and enhance
test accessibility.
Growing
awareness about the benefits of early diagnosis and preventive care has led to
increased patient engagement and proactive health management. This trend
significantly influences the demand for diagnostic tests. Increased awareness
about the importance of preventive healthcare encourages patients to seek
regular screenings and diagnostic tests. Educational campaigns and health
awareness programs drive demand for IVD products. Patients are becoming more
proactive in managing their health, seeking out diagnostic tests to detect
potential issues before they become severe. This shift in behavior supports
market growth for preventive diagnostic solutions. The rise of digital health
tools and apps that provide information about preventive care and health
tracking further promotes patient engagement and increases demand for
diagnostic tests. Companies should leverage health awareness trends by
providing educational resources and promoting the benefits of early diagnosis.
Developing patient-centric diagnostic solutions and integrating with digital
health platforms can enhance market penetration and growth.
Government
policies and health initiatives that prioritize preventive care and early
diagnosis play a significant role in driving the IVD market. These policies
often include funding and support for diagnostic testing and preventive
programs. Government funding and subsidies for preventive health programs and
screenings create a favorable environment for the adoption of diagnostic tests.
This support boosts demand for IVD products. Policies that incentivize the
development and use of preventive diagnostic technologies can drive innovation
and market growth. Regulatory support for new diagnostic tests aligns with
preventive healthcare goals. Government-led public health campaigns focusing on
early diagnosis and disease prevention increase the visibility and demand for
diagnostic tests. Companies should engage with policymakers and participate in
health initiatives to align with supportive government policies. Leveraging
funding opportunities and regulatory incentives can drive product adoption and
market expansion.
 Market 1.jpg)
Download Free Sample Report
Key Market Challenges
Regulatory and Compliance
Issues
The
regulatory environment for IVD products in Mexico is complex and evolving.
Companies must navigate a range of regulations and compliance requirements set
by various authorities, including the Federal Commission for Protection against
Sanitary Risk (COFEPRIS). The stringent and sometimes ambiguous regulatory
framework can create barriers to market entry and expansion.
The
process of obtaining regulatory approval for new IVD products can be lengthy
and cumbersome, leading to delays in market entry. This can hinder the ability
of companies to introduce innovative products in a timely manner. Ensuring
compliance with regulatory requirements involves significant costs related to
clinical trials, documentation, and quality assurance processes. These costs
can be particularly challenging for smaller companies or new entrants. Frequent
changes or updates in regulations can create uncertainty for companies,
impacting their strategic planning and investment decisions. To overcome
regulatory challenges, companies should invest in understanding and adapting to
local regulatory requirements. Engaging with regulatory consultants, building
strong relationships with regulatory bodies, and staying informed about
regulatory changes can help mitigate these challenges and streamline the
approval process.
Economic Constraints and
Healthcare Funding
Economic
constraints and limitations in healthcare funding are significant challenges
impacting the growth of the IVD market in Mexico. Despite economic growth,
disparities in income and healthcare access can affect the overall market for
diagnostic products.
Limited
budgets for public health initiatives and diagnostic testing can restrict the
availability and adoption of advanced IVD technologies. This is particularly
relevant in public healthcare settings where cost considerations are paramount.
Inadequate insurance coverage for certain diagnostic tests can limit patient
access and reduce demand for high-cost IVD products. Economic disparities
between different regions and socioeconomic groups can affect the distribution
and utilization of IVD products. Areas with lower economic activity may face
challenges in adopting advanced diagnostic technologies. To address economic
constraints, companies can explore cost-effective solutions and value-based
pricing models. Collaborating with government agencies and healthcare providers
to increase funding for diagnostic services and improve insurance coverage can
also enhance market access and growth opportunities.
Market Fragmentation and
Competition
The
IVD market in Mexico is characterized by fragmentation and intense competition
among both local and international players. The diverse range of diagnostic
needs and the presence of multiple market segments can create challenges for
companies trying to establish a strong market presence.
Intense
competition among established players and new entrants can lead to price wars
and reduced profit margins. Companies must differentiate their products through
innovation and quality to maintain a competitive edge. Some segments of the IVD
market may become saturated with similar products, making it challenging for
companies to gain market share and achieve sustainable growth. The distribution
network for IVD products can be fragmented, with varying levels of access and
infrastructure across different regions. This can impact the efficiency of
product distribution and market penetration.
To
navigate market fragmentation and competition, companies should focus on
differentiating their products through innovation and advanced features.
Building strong distribution networks, forming strategic partnerships, and
targeting underserved market segments can help enhance market presence and
achieve growth.
Key Market Trends
Rise of Personalized Medicine
and Precision Diagnostics
Personalized
medicine and precision diagnostics are transforming the healthcare landscape by
focusing on tailored treatment plans based on individual genetic,
environmental, and lifestyle factors. This trend is driving the demand for
advanced diagnostic tools that provide detailed insights into individual health
profiles.
There
is an increasing need for genetic testing and molecular diagnostics to identify
genetic predispositions to diseases and tailor treatments accordingly. This
trend is spurring the growth of molecular diagnostic reagents and platforms
that enable comprehensive genetic analysis. As treatments become more
personalized, the demand for diagnostics that can guide targeted therapies and
monitor treatment efficacy grows. This includes assays and tests that can
measure biomarkers relevant to specific diseases. Advances in genomics,
proteomics, and metabolomics are leading to the development of novel diagnostic
technologies, such as next-generation sequencing (NGS) and liquid biopsy, which
are gaining traction in the Mexican market. Companies investing in personalized
diagnostics and precision medicine will likely experience growth due to
increasing demand for individualized healthcare solutions. Collaborations with
research institutions and healthcare providers to develop and validate new
diagnostic tools will be critical for leveraging this trend.
Expansion of Point-of-Care
Testing (POCT)
Point-of-care
testing (POCT) refers to diagnostic tests conducted at or near the site of
patient care, providing rapid results and enabling immediate clinical
decisions. The expansion of POCT is driven by the need for quicker diagnoses
and more accessible testing solutions.
POCT
devices enhance access to diagnostic testing in remote or underserved areas,
which is particularly relevant for a country like Mexico with diverse
healthcare accessibility. The demand for immediate test results for conditions
such as diabetes, cardiovascular diseases, and infectious diseases drives the
development of advanced POCT technologies. This trend is leading to the growth
of portable and user-friendly diagnostic devices. POCT solutions are
increasingly integrated with digital health platforms, enabling remote
monitoring and telemedicine applications. This integration enhances patient
management and expands the reach of diagnostic services. Investing in the
development and distribution of POCT devices will allow companies to tap into
emerging market segments and address the need for faster, more accessible
diagnostic solutions. Partnerships with healthcare providers and technology
companies to integrate POCT with digital health solutions can further amplify
growth opportunities.
Focus on Chronic Disease
Management
The
increasing prevalence of chronic diseases such as diabetes, cardiovascular
conditions, and cancer is driving demand for continuous and accurate monitoring
solutions. Effective management of chronic diseases relies heavily on regular
diagnostic testing and monitoring.
There
is a growing need for diagnostic tools that provide continuous or frequent
monitoring of chronic conditions. This includes glucose monitoring systems for
diabetes and lipid panels for cardiovascular health. Advances in predictive
diagnostics are enabling early detection and risk assessment of chronic
diseases, allowing for timely interventions and better disease management. The
focus on chronic disease management is also driving the development of
patient-centric diagnostic solutions that are user-friendly and support
self-testing and home monitoring. Companies that focus on developing innovative
diagnostic solutions for chronic disease management will benefit from the
expanding market. Engaging in research and development to create advanced
monitoring devices and predictive diagnostic tools will be crucial for meeting
the growing demand in this area.
Segmental Insights
Technique Insights
Based
on the category of Technique, the Immuno Diagnostics segment emerged as the
dominant in the Mexico In-Vitro Diagnostics (IVD) Market in 2023. The Immuno
Diagnostics segment holds a dominant position in the Mexico In-Vitro
Diagnostics (IVD) market, driven by various factors that align with the broader
market dynamics and specific needs within the region. ELISA is a widely used
technique due to its high sensitivity and specificity in detecting antigens and
antibodies. In Mexico, the prevalence of infectious diseases such as dengue
fever, HIV, and hepatitis B and C has driven the demand for ELISA-based tests.
The ability of ELISA to provide rapid and accurate results is crucial for early
diagnosis and treatment, enhancing patient outcomes and reducing healthcare
costs. CLIA techniques are gaining traction due to their superior sensitivity
and the ability to automate processes, thus increasing throughput and
efficiency in diagnostic laboratories. In Mexico, the rise of chronic diseases
like diabetes and cardiovascular conditions has necessitated advanced
diagnostic tools that CLIA offers. These tests are pivotal in monitoring
disease markers and managing long-term patient care, contributing significantly
to the segment's dominance.
Though
less common due to safety concerns related to radioactivity, RIA is still
utilized in specialized settings for its exceptional sensitivity in detecting
hormones and drugs at very low concentrations. In Mexico, the application of
RIA in endocrinology, particularly in thyroid function tests and reproductive
health, underscores its relevance. Despite its niche usage, RIA remains a
critical component of the immuno diagnostics landscape. The need for
point-of-care testing (POCT) in remote and underserved areas has propelled the
use of rapid immunoassays. These tests offer quick results, which are essential
in controlling outbreaks and managing infectious diseases in real-time. In
Mexico, the implementation of rapid tests for conditions such as COVID-19 and
sexually transmitted infections has been crucial in public health initiatives,
enhancing the segment's market share. These factors are expected to drive the
growth of this segment.
Product Insights
The
Reagent segment is projected to experience rapid growth during the forecast
period. The Reagent segment plays a pivotal role in the Mexico In-Vitro
Diagnostics (IVD) market, dominating through its comprehensive range of
products that cater to diverse diagnostic needs. This dominance is underpinned
by the critical role reagents play in various diagnostic procedures, their
continuous innovation, and the strategic market dynamics within Mexico. Clinical
chemistry reagents are essential for a broad spectrum of tests including
glucose levels, liver function tests, and renal function assessments. In
Mexico, the rising prevalence of chronic diseases such as diabetes and liver
disorders necessitate reliable and accurate testing. Clinical chemistry
reagents provide the precision needed for these assessments, ensuring accurate
diagnosis and effective monitoring, which is crucial for managing long-term
conditions.
Immunoassay
reagents are fundamental for detecting hormones, proteins, and markers of
infectious diseases. The increasing incidence of infectious diseases like
dengue, HIV, and hepatitis in Mexico has driven the demand for high-quality
immunoassay reagents. These reagents enable sensitive and specific detection of
antigens and antibodies, facilitating early diagnosis and improving patient
outcomes, thus reinforcing their market dominance. The growth of personalized
medicine and the need for precise genetic testing have elevated the importance
of molecular diagnostic reagents. In Mexico, the application of these reagents
in detecting genetic disorders, infectious agents, and cancer markers is
expanding. The ability to provide rapid and accurate molecular data supports
targeted therapies and personalized treatment plans, highlighting the strategic
importance of molecular diagnostic reagents in the market. These factors
collectively contribute to the growth of this segment.
 Market 2.jpg)
Download Free Sample Report
Regional Insights
North
Mexico emerged as the dominant in the Mexico In-Vitro Diagnostics (IVD) Market
in 2023, holding the largest market share in terms of value. The North Mexico
region holds a dominant position in the Mexico In-Vitro Diagnostics (IVD)
market due to a combination of economic, healthcare, and demographic factors.
This dominance is driven by the region's advanced healthcare infrastructure,
significant investments in medical technology, and strategic geographic
advantages. The economic strength of North Mexico is a crucial driver of its
dominance in the IVD market. The region includes economically prosperous states
such as Nuevo León, Coahuila, and Chihuahua, which have higher per capita
income compared to other regions in Mexico. This economic prosperity translates
into better-funded healthcare systems, enabling the acquisition and utilization
of advanced diagnostic technologies. The strong industrial base in this region
also supports the growth of local manufacturing and distribution of IVD
products, enhancing market accessibility and reducing costs.
North
Mexico boasts some of the most advanced healthcare facilities in the country,
including renowned hospitals and specialized diagnostic centers. Cities like
Monterrey are home to leading medical institutions that offer comprehensive
diagnostic services, utilizing state-of-the-art IVD technologies. The presence
of these advanced facilities attracts patients from across Mexico and even from
neighboring countries, boosting the demand for IVD tests and services in the
region. Additionally, the availability of well-trained healthcare professionals
ensures high-quality diagnostic care, reinforcing the region’s market
leadership. The strategic geographic location of North Mexico, particularly its
proximity to the United States, offers significant advantages. This proximity
facilitates easier and faster access to advanced medical technologies and
innovations from the US, allowing the region to stay at the forefront of
diagnostic advancements. Moreover, cross-border healthcare collaborations and
partnerships enhance the availability and quality of IVD products and services
in North Mexico. The region also benefits from efficient logistics and supply
chain networks, ensuring timely delivery of diagnostic reagents and equipment.
Recent Developments
- In June 2023, Mexican Regulators Revise Classification Rules for IVD Medical Devices. Mexico's Ministry of Health has updated the classification requirements for in vitro diagnostic (IVD) devices. The revised Rule 26 now includes Class II IVDs for determining the infectious load of critical diseases essential for patient management. Additionally, tests for detecting HIV, HCV, HBV, HTLV infections, as well as HIV screening for blood donors and diagnostic testing of blood for HIV, will now be classified as Class III. This classification applies to first-line, confirmatory, and supplementary trials.
Key Market Players
- BIOMÉRIEUX
SA
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Becton, Dickinson and Company
- Bio-Rad Laboratories Inc
- Abbott Laboratories Inc.
- Sysmex Corporation
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc
- Seegene Inc
|
By
Technique
|
By
Product
|
By
Usability
|
By
Application
|
By
End User
|
By
Region
|
- Clinical
Chemistry
- Molecular
Diagnostics
- Immuno
Diagnostics
- Hematology
- Other
|
|
- Disposable
IVD Devices
- Reusable
IVD Devices
|
- Infectious
Disease
- Cancer/Oncology
- Cardiology
- Autoimmune
Disease
- Diabetes
- Nephrology
- Other
|
- Diagnostic
Laboratories
- Hospitals
and Clinics
- Other
|
- North
Mexico
- Central
Mexico
- South
Mexico
|
Report Scope:
In this report, the Mexico In-Vitro Diagnostics
(IVD) Market has been segmented into the following categories, in addition to
the industry trends which have also been detailed below:
- Mexico In-Vitro Diagnostics (IVD) Market, By Technique:
o Clinical Chemistry
o
Molecular
Diagnostics
o
Immuno
Diagnostics
o
Hematology
o
Other
- Mexico In-Vitro Diagnostics (IVD) Market, By Product:
o Instrument
o
Reagent
o
Other
- Mexico In-Vitro Diagnostics (IVD) Market, By Usability:
o Disposable IVD Devices
o
Reusable IVD Devices
- Mexico In-Vitro Diagnostics (IVD) Market, By Application:
o Infectious Disease
o
Cancer/Oncology
o
Cardiology
o
Autoimmune Disease
o
Diabetes
o
Nephrology
o
Other
- Mexico In-Vitro Diagnostics (IVD) Market, By End User:
o Diagnostic Laboratories
o
Hospitals and Clinics
o
Other
- Mexico In-Vitro Diagnostics (IVD) Market, By
Region:
o North Mexico
o Central Mexico
o South Mexico
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Mexico
In-Vitro Diagnostics (IVD) Market.
Available Customizations:
Mexico In-Vitro Diagnostics (IVD) market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Mexico In-Vitro
Diagnostics (IVD) Market is an upcoming report to be released soon. If you wish
an early delivery of this report or want to confirm the date of release, please
contact us at [email protected]